Open Label Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Daily Oral Dosing of YCT-529 for 28 Days in Healthy Men
Latest Information Update: 16 Apr 2025
At a glance
- Drugs YCT 529 (Primary)
- Indications Pregnancy
- Focus Adverse reactions
- Sponsors YourChoice Therapeutics
- 09 Apr 2025 Planned number of patients changed from 50 to 66.
- 09 Apr 2025 Planned End Date changed from 28 Feb 2026 to 31 Jul 2026.
- 09 Apr 2025 Planned primary completion date changed from 28 Feb 2026 to 31 Jul 2026.